Global regulatory strategy has become less about creating a plan and more about creating a plan that can change.
Regulatory requirements continue to evolve across markets, while companies are managing more products, more submissions, and more regulatory dependencies. A strategy that works well at the beginning of a product’s lifecycle may need to change as market priorities shift, new requirements emerge, or a regulatory pathway takes an unexpected turn. Having a strategy in place for global market access is a necessity regardless of the stage.
That was the focus of my recent webinar, Building Global Regulatory Strategies in a Rapidly Evolving Landscape.
Watch the webinar replay
In the session, I focused on a question I hear frequently from regulatory teams: How do you build a global strategy that gives you enough structure to move forward while still allowing you to adapt when conditions change?
For me, the answer starts with moving regulatory strategy further upstream.
Regulatory strategy starts before the submission
A global regulatory strategy should influence decisions well before a submission is being prepared.
Market selection, product development, commercial priorities, evidence generation, and submission sequencing are all connected. When regulatory is brought into those conversations early, the team has an opportunity to identify constraints and opportunities before they become timeline problems.
That means looking beyond the question of Where can we get approved?
The more useful questions are:
- Which markets should we prioritize?
- In what sequence should we enter them?
- What requirements could influence that sequence?
- What information or approvals can be used to your advantage to support subsequent market growth?
- Where are the regulatory uncertainties that could change the plan?
These decisions can have a significant impact on how efficiently a company expands globally.
Market sequencing should be strategic, not simply chronological
One of the areas covered during the webinar was submission sequencing.
It is tempting to look at global expansion as a series of individual submissions: complete one, move to the next, and continue down the list.
But regulatory teams can create more flexibility by looking at the markets collectively.
An approval, assessment, or body of evidence from one market may influence the approach in another. At the same time, the most commercially important market is not always the market that should come first from a regulatory perspective.
That is where regulatory strategy becomes more than submission planning.
The goal is to understand the relationships between markets and make sequencing decisions based on the broader product and business strategy.
Regulatory intelligence needs to reach beyond the regulatory team
Another important part of an agile strategy is how regulatory intelligence is used.
Regulatory teams can monitor changes continuously, but the value of that information comes from understanding what those changes mean for the business.
A new requirement may affect a product already on the market. A change in guidance may influence an upcoming submission. A regulatory development in one country may create an opportunity or constraint in another.
That information can therefore affect decisions across regulatory, quality, product, clinical, and commercial teams.
The question becomes less about What changed? and more about What does this change mean for what we are planning to do?
That shift is important because it moves regulatory intelligence from a monitoring activity into a strategic input.
Build the strategy around change
Even the best regulatory plan will encounter uncertainty.
A review may take longer than expected. A regulator may request additional information. A market may change its requirements. A planned pathway may no longer be the most practical option.
Agile regulatory strategy accounts for those possibilities before they happen.
That means identifying potential triggers, defining scenarios, and understanding what the team would do if the original plan changes.
For example, if a submission is delayed, what does that mean for the next market? If a regulatory requirement changes while a product is in development, which teams need to know? If a market becomes a higher priority commercially, can the regulatory strategy accommodate that change?
Planning for those scenarios gives regulatory teams more options when they need them.
Regulatory strategy is a continuous process
Perhaps the biggest takeaway from the webinar is that global regulatory strategy should not be treated as a one-time exercise.
The strategy needs to evolve as the product evolves, markets change, new regulatory information becomes available, and the business establishes new priorities.
That requires visibility across the regulatory lifecycle and a way to connect intelligence, market requirements, submission plans, changes, and decisions.
When those pieces are connected, regulatory teams can spend less time reconstructing what is happening across markets and more time determining what should happen next.
That is what makes a global regulatory strategy truly agile: having a clear direction while maintaining the visibility and flexibility to change course when the regulatory environment requires it.
In the full webinar, I walk through the framework in more detail, including how to prioritize markets, sequence submissions, identify strategic triggers, use regulatory intelligence to inform decisions, and build contingency planning into a global regulatory strategy.
Ready to put an agile regulatory strategy into action? RegDesk connects regulatory intelligence, submissions, change assessment, and tracking in one RIM platform, helping teams turn regulatory information into clear next steps across markets. Talk with our team to see how RegDesk can support a more connected, proactive approach to global regulatory operations.
